Cassava Sciences hit with FDA request for more data on simufilam trial
Source: SeekingAlpha
2025-12-03 07:21:54 ET
More on Cassava Sciences
- Cassava Sciences: Fundamentals Update After Big Move On Insider Purchases
- Cassava Sciences spikes as CEO buys stock
- Cassava Sciences files $200M mixed securities shelf
- Seeking Alpha’s Quant Rating on Cassava Sciences
- Historical earnings data for Cassava Sciences
Read the full article on Seeking Alpha
For further details see:
Cassava Sciences hit with FDA request for more data on simufilam trial
Cassava Sciences Inc.
NASDAQ: SAVA
SAVA Trading
15.14% G/L:
$2.395 Last:
1,546,293 Volume:
$2.19 Open:
SAVA Latest News
March 12, 2026 08:00:00 am
Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
SAVA Stock Data
$106,035,832
47,148,506
2.07%
34
N/A
Biotechnology & Life Sciences
Healthcare
US
Austin
